Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

  title={Reducing Endogenous Tau Ameliorates Amyloid {\ss}-Induced Deficits in an Alzheimer's Disease Mouse Model},
  author={Erik D. Roberson and Kimberly Scearce-Levie and Jorge J. Palop and Fengrong Yan and Irene Han-Juo Cheng and Tiffany Wu and Hilary Gerstein and Gui-qiu Yu and Lennart Mucke},
  pages={750 - 754}
Many potential treatments for Alzheimer's disease target amyloid-β peptides (Aβ), which are widely presumed to cause the disease. The microtubule-associated protein tau is also involved in the disease, but it is unclear whether treatments aimed at tau could block Aβ-induced cognitive impairments. Here, we found that reducing endogenous tau levels prevented behavioral deficits in transgenic mice expressing human amyloid precursor protein, without altering their high Aβ levels. Tau reduction also… 

Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model

The results suggest that tau oligomerization is not only a consequence of Aβ pathology but also a critical mediator of the toxic effects observed afterward in AD, and support the potential of t Tau oligomers as a therapeutic target for AD.

Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease

The results indicate that Aβ, tau, and Fyn jointly impair synaptic and network function and suggest that disrupting the copathogenic relationship between these factors could be of therapeutic benefit.

Reducing tau ameliorates behavioural and transcriptional deficits in a novel model of Alzheimer’s disease

It is found that Aβ and tau work cooperatively to cause a hyperactivity phenotype and to cause downregulation of gene transcription including many involved in synaptic function, suggesting that lowering tau levels, particularly at the synapse, may be beneficial in AD.

Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport

A mechanism for the protective effects of tau reduction in mouse models of Alzheimer’s disease is identified, and it is shown that Aβ requires tau to impair axonal transport, and t Tau reduction protects against Aβ-induced axonal Transport defects.

Tau reduction in the presence of amyloid-&bgr; prevents tau pathology and neuronal death in vivo

Results suggest that, although amyloid-β stabilizes tau aggregates, lowering total tau levels is still an effective strategy for the treatment of tau pathology and neuronal loss even in the presence of amyloids-β deposition.

Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease

A lipidomics approach was used to generate a broad profile of fatty acids in brain tissues of hAPP-expressing mice and found an increase in arachidonic acid and its metabolites, suggesting increased activity of the group IV isoform of phospholipase A2 (GIVA-PLA2).

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

It is found that selenate stabilizes PP2A-tau complexes and mitigates tau pathology in several AD models, making it a promising lead compound for tau-targeted treatments of AD and related dementias.



Tau is essential to β-amyloid-induced neurotoxicity

Evidence is provided supporting a key role for tau in the mechanisms leading to Aβ-induced neurodegeneration in the central nervous system and the analysis of the composition of the cytoskeleton of tau-depleted neurons suggested that the formation of more dynamic microtubules might confer resistance to A β-mediated neurodegenersation.

Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

NFTs are not sufficient to cause cognitive decline or neuronal death in this model of tauopathy, and after the suppression of transgenic tau, memory function recovered, and neuron numbers stabilized, but to the authors' surprise, NFTs continued to accumulate.

Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits

The tight link between Aβ-induced cognitive deficits and neuronal depletion of CB and c-Fos suggests an involvement of calcium-dependent pathways in AD-related cognitive decline and could facilitate the preclinical evaluation of novel AD treatments.

Behavioral phenotypes of amyloid‐based genetically modified mouse models of Alzheimer's disease

A detailed review of the behavioral and cognitive deficits present in several transgenic mouse models of AD are provided and their functional changes in response to experimental treatments are discussed.

A specific amyloid-β protein assembly in the brain impairs memory

It is found that memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-β assembly, which is proposed to be Aβ*56 (Aβ star 56), which may contribute to cognitive deficits associated with Alzheimer's disease.

Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP

The results indicate that either APP or Aβ influences the formation of neurofibrillary tangles and supports the hypothesis that a similar interaction occurs in Alzheimer's disease.

Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease.

It is proposed that this type of delay, played out among thousands of plaques throughout neocortical areas, disrupts the precise temporal firing patterns of action potentials, contributing directly to neural system failure and dementia.

High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

It is concluded that Aβ is synaptotoxic even in the absence of plaques and that high levels of Aβ1–42 are insufficient to induce plaque formation in mice expressing wild-type hAPP, supporting the emerging view that plaque-independent Aβ toxicity plays an important role in the development of synaptic deficits in AD and related conditions.